Author Affiliation: Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Ore.
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancy
and 90% to 95% of neoplasms arising from the kidney.1 It
is the sixth leading cause of cancer death in the United States.2 Approximately
31 200 new cases of RCC were diagnosed in the United States in 2000 and
more than 11 900 affected individuals died. This disease often presents
with few symptoms but it can have diverse paraneoplastic manifestations. It
displays relative resistance to radiation and chemotherapy, although there
have been occasional durable responses to interleukin 2 (IL-2)–based
immunotherapy. Recent insights into the genetic changes associated with RCC
have provided new targets for therapy.
Curti BD. Renal Cell Carcinoma. JAMA. 2004;292(1):97-100. doi:10.1001/jama.292.1.97